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Abstract Fibrates are hypolipidemic drugs that activate the
peroxisome proliferator-activated receptors. Since fibrates may
also increase energy expenditure, we investigated whether
fenofibrate (FF) had this effect in diet-induced obese rats. A
2-month administration of a high-fat palatable diet to adult rats
increased body weight by 25% and white adipose mass by 163%
compared with a standard diet. These effects were prevented by
FF, both when administered for the 2 months of high-fat feeding
and when given for only the second month. Consequently, FF-
treated rats had a final body weight and white adipose tissue
mass similar to untreated animals on the standard diet. FF also
increased resting metabolic rate, hepatic peroxisomal and
mitochondrial palmitoyl-dependent oxygen uptake and mRNA
levels of acyl-CoA oxidase and lipoprotein lipase. Finally, FF
lowered mRNA levels of uncoupling protein-2 and did not affect
mitochondrial respiration in skeletal muscle. Therefore, FF
seems to act as a weight-stabilizer mainly through its effect on
liver metabolism. ß 2001 Federation of European Biochemical
Societies. Published by Elsevier Science B.V. All rights re-
served.
Key words: Fibrate; Obesity; Fatty acid; Peroxisome;
Mitochondrion; Liver
1. Introduction
Fibrates are a class of drugs widely used to treat dyslipi-
demic patients, thus reducing the risk of developing coronary
heart disease [1]. The molecular mechanism underlying the
e¡ect of ¢brates has been elucidated [2]. Fibrates bind to
and activate speci¢c transcription factors belonging to the
nuclear hormone receptor superfamily, the peroxisome prolif-
erator-activated receptors (PPARs). These receptors form het-
erodimers with the retinoid X receptor and bind to peroxi-
some proliferator response elements in the promoter region of
target genes, whose transcription rate is consequently regu-
lated [3,4]. Among the three principal isoforms so far identi-
¢ed (PPARK, PPARL and PPARQ), PPARK seems to mediate
the hypotriglyceridemic e¡ect of ¢brates by inducing high
rates of mitochondrial and peroxisomal L-oxidation in liver,
kidney, heart and muscle [5,6] and by decreasing the plasma
concentration of triacylglycerol-rich lipoproteins.
An intriguing aspect of ¢brates is their potential role as
regulators of energy homeostasis. It has been reported that
feno¢brate (FF) does not a¡ect body weight in Sprague^Daw-
ley rats [7]. On the other hand, mice lacking PPARK, are
obese, no longer responsive to peroxisome proliferators and
fail to induce the expression of genes required for fatty acid
metabolism in mitochondria and peroxisomes [8,9]. In addi-
tion, there is evidence that FF can reduce body weight gain in
animal models of diabetes, obesity and insulin-resistance such
as fatty fa/fa Zucker rats and high-fat-fed C57Bl/6 mice
[10,11].
Therefore, it might be possible that FF a¡ects energy ho-
meostasis only in the presence of an altered £ux of fatty acids.
It is well known that lipids accumulated in the adipose tissue
largely derive from circulating triacylglycerols, especially dur-
ing high-fat feeding. Thus, increased fatty acid oxidation in
liver may play an important role in the regulation of body
weight. In this scenario, the modulation of genes related to
energy expenditure, such as uncoupling proteins (UCPs), may
be involved. Recent evidence, in fact, indicates that, at least in
mice, ¢brates regulate UCP gene expression [12,13]. UCPs are
mitochondrial carriers capable of dissipating the proton gra-
dient across the mitochondrial inner membrane thus increas-
ing thermogenesis while reducing the e⁄ciency of ATP syn-
thesis [14]. UCP-2 and UCP-3 may be relevant for the energy
balance regulation because of their location in metabolically
important tissues [15,16].
The aim of our study was to investigate whether FF in-
creases energy expenditure, thus preventing body weight
gain and increased adiposity, in diet-induced obese rats. We
also veri¢ed whether FF reduces body weight gain after over-
weight had already been established in rats by high-fat feed-
ing. In all animals we measured the gene expression of
PPARs, their target genes and UCPs, as well as fatty acid
oxidation in liver and in skeletal muscle. As both mitochon-
dria and peroxisomes are very sensitive to ¢brates [17,18], we
extended the biochemical analyses to both organelles.
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2. Materials and methods
2.1. Rat treatment
2-Month-old male Wistar rats (Charles River, Lecco, Italy) were
kept one per cage in a temperature-controlled room at 28‡C with a
12/12 h light/darkness cycle and allowed free access to water and food.
Animals were cared for in accordance with national guidelines cover-
ing animal experiments. The rats were divided into four groups. One
(C) was fed a standard diet (15.9 kJ gross energy/g) for 2 months. The
other three groups were fed a palatable high-fat diet (19.8 kJ gross
energy/g) for 2 months [19]. Group D received only the high-fat diet;
group DF1 was dosed orally once a day with FF (kindly provided by
Fournier Pharma, Segrate, Italy) at a dose of 320 mg/kg body weight
suspended in 1% carboxymethylcellulose only during the second
month [20,21]; group DF2 was given the FF treatment simultaneously
to the high-fat diet, and therefore received the drug for 2 months.
Suspension vehicle was administered orally once a day to animals not
receiving FF. Body weight and food intake were monitored daily.
Rats were killed by decapitation; liver and gastrocnemius muscle
were excised, weighed and either immediately processed for the prep-
aration of homogenates or immediately frozen in liquid nitrogen and
stored at 380‡C until further processing. Visceral white adipose tissue
(WAT) was removed and weighed.
2.2. Resting metabolic rate (RMR) measurement
The day before killing, the RMR of rats was measured using open-
circuit indirect calorimetry. Each rat was placed in a respiratory
chamber and air£ow was measured using an O2-ECO mass £ow con-
troller (Columbus Instruments International Corporation, Columbus,
OH, USA) as described elsewhere [22]. The RMR was measured at
28‡C between 11.00 and 16.00 h, which corresponds to the nadir of
energy expenditure [22].
2.3. Peroxisomal and mitochondrial palmitoyl-dependent oxygen uptake
Liver samples were homogenized with a Potter Elvehjem homoge-
nizer in a medium consisting of 220 mM mannitol, 70 mM sucrose, 20
mM Tris^HCl and 2 mM EDTA, pH 7.4. Peroxisomal palmitoyl-CoA
oxidase activity was measured polarographically according to previ-
ously published procedures using a Clark-type oxygen electrode [23].
Mitochondrial palmitoyl-dependent oxygen uptake was measured po-
larographically according to Estabrook [24].
2.4. Mitochondrial respiration
Mitochondria were prepared as described by Lanni et al. [25]. Mi-
tochondrial respiration was determined polarographically at 30‡C, in
a respiratory medium consisting of 80 mM KCl, 50 mM HEPES,
5 mM phosphate bu¡er, 10 nM Na-succinate, 3.75 WM rotenone
and 1% free fatty acid bovine serum albumin, pH 7.0. State 3 respi-
ration was initiated by the addition of 300 WM ADP, and the method
of Estabrook [24] was used to calculate state 4 and 3 respiration and
respiratory control ratio (RCR).
2.5. Reverse transcriptase-polymerase chain reaction (RT-PCR)
analysis
Total RNA from homogenized tissues was extracted using the gua-
nidinium thiocyanate^phenol^chloroform method [26] followed by
DNase treatment for 15 min at 25‡C.
Gene expression was evaluated by semi-quantitative RT-PCR using
a thermocycler (MJ Research PTC-100, Waltham, MA, USA). cDNA
was synthesized by RT from 2 Wg of total RNA using a mutagenized
Moloney murine leukemia virus RT (Superscript1 II RT, Life Tech-
nologies Italia, San Giuliano Milanese, Italy). A negative control was
obtained by omitting the RT in the cDNA synthesis reaction and
performing a standard PCR using selective oligonucleotide primers.
The sequences of the sense and antisense primers were: 5P-TCAC-
TCGAAGCCAGCGTTAT-3P and 5P-TCTTCAGGTAGCCGTT-
ATCCA-3P for acyl-CoA oxidase (ACO), 5P-TCATCAACTGGCTG-
GAGGAAG-3P and 5P-TATGCCTTGCTGGGGTTTTCT-3P for
lipoprotein lipase (LPL), 5P-CGCATTGGCTCTACGACTCT-3P, 5P-
ATCAAGCGGAGGAAGGAAG-3P for the UCP-2, and 5P-ACA-
GGCAGCAAAGGAACCAG-3P and 5P-AACAGGTGAGAGTCC-
AGCAG-3P for the UCP-3. As internal control for each sample, am-
pli¢cation of a fragment from the glyceraldehyde 3-phosphate
dehydrogenase (GAPDH) gene was performed, using primers that
were previously reported [27]. PCRs yielded products of 564, 454,
557 and 876 bp for ACO, LPL, UCP-2 and GAPDH, respectively.
The ampli¢cation products were electrophoretically separated on a
2% agarose gel containing ethidium bromide. UV-stimulated £uores-
cence was captured using a digital videocamera and quantitated with
the NIH Image v.1.59 software (National Institutes of Health, Bethes-
da, MD, USA). Linearity of the PCR was tested by amplifying in-
creasing amounts of the various cDNA (from 0.1- to 10-fold the
amount of cDNA used for a standard PCR) at various numbers of
cycles and was found to be between 30 and 40 cycles. Data points
from the linearity experiments were used to draw a standard curve;
experimental values were transformed by interpolation on the stan-
dard curve and normalized to the GAPDH values.
2.6. Microscopic examination
Small pieces of liver were ¢xed for 2 h at 4‡C in Karnovsky medium
[28] and post¢xed for 1 h at 4‡C in 1% osmium tetroxide. Following
¢xation, the pieces were dehydrated in a graded ethanol series and
embedded in Epon 812. Sections 1 Wm thick were stained with hema-
toxylin and eosin for microscopic examination.
2.7. Statistics
Results are expressed as means þ S.E.M. The statistical signi¢cance
of between-group di¡erences was determined by ANOVA followed by
a Student^Neuman^Keuls test. Di¡erences were considered signi¢cant
when P was at least less than 0.05.
3. Results
3.1. Body weight gain and adiposity in C, D, DF1 and DF2
animals
As shown in Fig. 1, in adult normal rats, administration of
the high-fat palatable diet for 2 months, signi¢cantly increased
body weight by 25% (571 g in D and 456 g in C rats). The
simultaneous treatment of DF2 rats with FF prevented the
excess body weight gain, thus yielding a ¢nal weight of DF2
animals (477 g) similar to C rats and 16% lower than D rats.
To evaluate whether FF was also able to reduce body weight
in an early stage of obesity, we administered FF to DF1 rats
Fig. 1. E¡ect of FF on high-fat diet-induced body weight gain.
Body weights are expressed as the mean þ S.E.M.; n = 7^8. Body
weights at the end of treatment: there were signi¢cant di¡erences
(ANOVA, P6 0.05) in body weights between D and the other
groups. C = rats on a standard diet for 2 months; D = rats on a
high-fat diet for 2 months; DF1 = rats on a high-fat diet for
2 months, treated with FF only during the second month; DF2 =
rats on a high-fat diet and treated with FF for 2 months.
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after 1 month of high-fat diet. At this time point, the body
weight of DF1 rats was already signi¢cantly higher than C
rats (439 g in DF1 and 380 g in C rats; +16%). The admin-
istration of FF for just 1 month to DF1 rats not only reduced
body weight gain (490 g; 314% compared to D rats), but this
e¡ect was stronger in comparison to the DF2 group. In fact,
during the last 30 days of the experiment the weight gain in
DF1 rats was only 51 g as compared with 82 g in DF2 rats. In
the same time frame, the body weight gain of D and C ani-
mals was 124 and 76 g, respectively.
As shown in Table 1 the visceral WAT mass was signi¢-
cantly increased in group D (+163%) when compared with
group C (41.1 and 15.7 g, respectively). FF greatly reduced
the WAT mass both when administered simultaneously and
when administered after 1 month of high-fat diet (23.8 g in
DF1 rats, 342% compared with D rats; 18.3 g in DF2 rats,
355% compared with D rats). When FF was administered to
rats on a standard diet there was no signi¢cant e¡ect on body
weight gain or WAT mass (data not shown).
By daily monitoring, we did not observe any in£uence of
FF on food intake (data not shown).
3.2. RMR
To verify if FF a¡ects total body metabolic rate, we mea-
sured oxygen consumption in whole animals (Table 1). Rest-
ing oxygen consumption in group D was the same as group C
(1.4 and 1.38 l O2/h/kg0:75 b.w., respectively). RMR was in-
creased in groups DF1 and DF2 compared with group D (+8
and +17%, respectively), although these di¡erences are not
statistically signi¢cant.
3.3. Peroxisomal and mitochondrial palmitoyl-dependent
oxygen uptake
A high-fat diet did not a¡ect the values of hepatic peroxi-
somal and mitochondrial palmitoyl-dependent oxygen uptake
in D rats, while FF administration to DF1 and DF2 rats
signi¢cantly increased both activities (Table 2). Mitochondrial
respiration was increased by 82 and 106% in groups DF1 and
DF2, respectively. The variations of peroxisomal respiration
were much more marked. The increases were of about 24- and
38-fold in DF1 and DF2, respectively. No variations were
found in skeletal muscle.
The liver mitochondrial respiration rate, measured with suc-
cinate as substrate, did not show signi¢cant variations in state
4 and state 3 respiration rate among the groups studied (Table
3). Only a reduction (about 315%) in RCR was found in
groups DF1 and DF2 compared with group D (6.3 and 6.1
versus 7.3, respectively). Similar results were obtained in skel-
etal muscle.
Table 1
In£uence of FF on liver and visceral WAT weight and RMR
C D DF1 DF2
WAT weight (g) 15.7 þ 1.9 (n = 4) 41.1 þ 3.5* (n = 4) 23.8 þ 7.4 (n = 4) 18.3 þ 3.5 (n = 4)
Liver weight (g) 14.9 þ 1.2 (n = 7) 18.7 þ 1.6 (n = 6) 25.3 þ 1.3** (n = 7) 26.8 þ 1.2** (n = 7)
RMR (l O2/h/kg0:75) 1.40 þ 0.06 (n = 4) 1.38 þ 0.11 (n = 4) 1.49 þ 0.09 (n = 4) 1.62 þ 0.12 (n = 4)
WAT, white adipose tissue. Results are presented as the mean þ S.E.M. *Ps 0.05 versus C, DF1 and DF2; **Ps 0.05 versus C and D.
Table 2
Hepatic mitochondrial and peroxisomal palmitoyl-dependent oxygen
uptake
Mitochondria Peroxisomes
C 5.37 þ 0.47 4.21 þ 1.1
D 5.01 þ 0.43 4.22 þ 1.5
DF1 9.10 þ 0.59* 101 þ 14.9*
DF2 10.33 þ 1.20* 161 þ 23.8**
The values are expressed as n atoms oxygen/min/mg protein of liver
homogenate. Data are mean þ S.E.M., n = 4^5. *P6 0.05 versus C
and D. **P6 0.05 versus C, D and DF1.
Fig. 2. RT-PCR analysis of gene expression in rat liver and skeletal
muscle. Vertical bars represent the level of mRNA of di¡erent genes
after normalization to the levels of GAPDH mRNA in the same
samples. Dotted lines indicate the levels of mRNA in group C. Ver-
tical lines indicate the S.E.M. Each group consisted of seven ani-
mals.
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3.4. Gene expression
The level of expression of several genes was determined in
liver and skeletal muscle (gastrocnemius) of rats belonging to
the four experimental groups by RT-PCR. We measured
mRNA of PPARK, PPARL, PPARQ1, PPARQ2, ACO, LPL,
UCP-2 and UCP-3. There were no signi¢cant variations in the
mRNA levels of PPARs in the animals treated with FF versus
untreated animals, except for PPARK, whose mRNA level
was slightly increased in liver of DF1 and DF2 rats (1.7-
fold; data not shown). On the contrary, 1 and 2 months of
treatment with FF up-regulated the steady state levels of ACO
mRNA (3.3-fold, DF1 or DF2 versus D) in liver (Fig. 2a).
Also LPL mRNA levels were increased in liver of FF-treated
rats receiving the high-fat diet (3.0-fold, DF1 or DF2 versus
D) (Fig. 2a). UCP-2 was a¡ected by FF only in muscle:
mRNA levels decreased by 3.3- and 2.2-fold after 1 and 2
months of treatment, respectively (Fig. 2b). Conversely,
muscle UCP-3 mRNA level did not change following FF ad-
ministration (Fig. 2b).
3.5. Liver microscopic examination
As shown in Fig. 3, in the hepatocytes of D rats there is a
lipid accumulation which is absent in hepatocytes of C rats.
This accumulation disappeared following FF treatment as
demonstrated in the hepatocytes of DF1 and DF2 rats.
4. Discussion
This study was undertaken to verify whether FF reduces
body weight in normal rats on high-fat feeding and to obtain
information about the cellular mechanism involved.
We observed that normal adult rats on a high-fat diet
gained more weight compared with rats on a standard diet
(¢nal weights 571 and 456 g, respectively). This e¡ect was not
observed in an earlier study [19], however in our study the diet
was given for a longer time (2 months versus 15 days) and our
animals were older (60 versus 30 days). The obesity-like con-
dition that we induced in rats mimics what occurs in humans
on a high-fat diet in the early stages of obesity. In fact, the
body weight gain of group D rats is largely due to an increase
of the WAT mass, while the weight of other organs and tis-
sues remained unchanged except for liver which showed stea-
tosis and a 26% weight increase.
An important ¢nding is that FF reduced the weight of rats
fed the high-fat diet for 2 months, compared with sex- and
age-matched untreated rats receiving the same diet. This was
also true for those animals who started FF 1 month after the
beginning of the high-fat diet. Interestingly, the ¢nal weight of
both groups of treated animals was very similar to that of
untreated animals on the standard diet. This indicates that,
in the presence of fat accumulation, FF not only prevents
excessive weight gain, but is also able to mobilize fats from
adipose tissue depots. It is also likely that both the prevention
of fat accumulation and fat mobilization in WAT are driven
by the increased fat catabolism in liver. In fact, in FF-treated
rats, the liver was even heavier than in group D rats, but
hepatocytes did not contain lipid droplets in contrast to he-
patocytes from group D rats. This ¢nding is in accordance
with the observation of liver hypertrophy after FF adminis-
tration, due to proliferation of peroxisomes and mitochon-
dria. Peroxisome respiration was greatly increased in DF2
rats (38-fold compared to C or D rats), which con¢rms that
FF induces marked peroxisome proliferation. Similarly, mito-
chondrial respiration was almost doubled in DF1 and DF2
animals. Moreover, although the respiration of puri¢ed mito-
chondria was unchanged (see Table 3), mitochondrial respira-
tion in liver homogenate was signi¢cantly increased (see Table
2), which indicates that the enhancement was due to an in-
creased number of mitochondria. It is noteworthy to report
that the increase in liver activity was paralleled by a large
reduction in WAT mass, which can account for most of the
body weight reduction. Also the increase in RMR of FF-
treated rats (+8 and +17% in DF1 and DF2, respectively)
may be accounted for by the increase in hepatic mitochondrial
and peroxisomal L-oxidation. In fact, it is well known, that
the liver contributes for about 10^20% to the RMR. There-
Table 3
E¡ect of FF on liver and gastrocnemius mitochondrial respiratory parameters
Liver Gastrocnemius
state 4 state 3 RCR state 4 state 3 RCR
C 23 þ 2.0 170 þ 28 7.4 þ 0.7 85 þ 6.1 449 þ 35 5.3 þ 0.3
D 25 þ 2.8 183 þ 18 7.3 þ 0.6 71 þ 6.4 364 þ 28 5.3 þ 0.7
DF1 28 þ 2.0 179 þ 8.0 6.4 þ 0.1 92 þ 8.5 449 þ 35 4.9 þ 0.3
DF2 27 þ 2.0 164 þ 21 6.1 þ 0.6 90 þ 9.0 462 þ 46 5.1 þ 0.4
The values of state 4 and state 3 are expressed as ng atoms of oxygen consumption/min/mg of protein; RCR, respiratory control ratio (state 3/
state 4 respiratory rates). Results are expressed as the mean þ S.E.M. of four experiments for each group. The di¡erences among all groups
were not statistically signi¢cant.
Fig. 3. Light microscopy of liver sections. White vacuoles represent
lipid droplets. C, D, DF1 and DF2 indicate the di¡erent groups of
rats as speci¢ed in the legend to Fig. 1.
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fore, a 100% increase of oxygen consumption by the liver
would explain an increase of RMR of the order of 8^17%.
To gain insight into the molecular mechanisms underlying
the e¡ects described above, we measured the mRNA levels of
PPARs because self-regulation of nuclear receptors by ligands
is reported [29,30] and FF binds strongly, although not ex-
clusively to PPARK. However, except for a slight 1.7-fold
increase of PPARK liver expression in FF-treated rats, no
variations in the expression of other PPAR isoforms were
observed in the di¡erent experimental conditions. We then
investigated genes involved in lipid metabolism and energy
expenditure (LPL, ACO, UCP-2 and UCP-3) and found
that LPL and ACO gene expression was up-regulated by FF
treatment in the presence of the high-fat diet. Although the
combined action of FF and the high-fat diet was not known,
the e¡ect on ACO and LPL expression was partly expected,
since these are targets of FF-activated PPARs [4], and thus
provide a positive control of the experimental conditions.
However, the association of the activation of these genes
and weight reduction is a novel ¢nding. Surprisingly in our
case, UCP-2 expression was not induced in the liver of D rats
where the number of lipid droplets was increased; FF did not
alter this situation. Di¡erently, UCP-2 expression may be in-
duced by lipid substrates in isolated hepatocytes [31]. These
apparently contrasting results may be explained by the di¡er-
ences between our in vivo experimental setting and the in vitro
one used by Cortez-Pinto et al. [31]. In contrast to liver, UCP-
2 expression in skeletal muscle was stimulated by the high-fat
diet and inhibited by FF. If UCP-2 is involved in lipid metab-
olism, this result may be in accordance with the increased
fatty acid in£ux and utilization in muscle consequent to a
hyperlipidic diet ; vice versa, when L-oxidation in liver is up-
regulated less fatty acids are available to muscles even when
the diet contains large amounts of lipids. Finally, we did not
observe variations in UCP-3 mRNA level in the muscle of rats
that were on the high-fat diet alone or in combination with
FF treatment. Interestingly, it has been reported that UCP-3
expression in rat muscle is increased after fasting, a condition
of altered energy intake di¡erent from high-fat feeding [32].
Thus, FF may exert an indirect e¡ect in muscle, which may be
related to its action in liver.
In conclusion, we provide evidence that FF acts as a
‘weight-stabilizer’ through enhancement of lipid catabolism
in rat liver. This e¡ect is mediated by PPARs, mainly through
the induction of target enzymes involved in hepatic lipid me-
tabolism. Although both the peroxisomal and the mitochon-
drial compartments contribute signi¢cantly to the increased
oxidation of fatty acids, our data do not support a role of
mitochondria in wasting energy, which is instead an intrinsic
property of peroxisomal L-oxidation. Skeletal muscle does not
seem to play a relevant role in dissipating energy, thus indi-
cating the liver as the major player in the e¡ects exerted by
FF on body weight and WAT mass in rodents.
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